Alector Inc.
Clinical trials sponsored by Alector Inc., explained in plain language.
-
New drug trial aims to slow Alzheimer's progression
Disease control CompletedThis study tested whether an investigational drug called AL002 could slow the progression of early Alzheimer's disease. 356 participants with early-stage Alzheimer's received either the drug or a placebo via intravenous infusion over 96 weeks. Researchers measured changes in memo…
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Experimental drug tested in people destined for dementia
Disease control CompletedThis study tested an experimental drug called AL001 in people who carry specific genetic mutations that cause frontotemporal dementia, a serious brain disease. The main goal was to check the drug's safety, how the body processes it, and its effects on certain biological markers. …
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC